DBS

Newronika Raises an 8.4M EUR Series-A Round

Retrieved on: 
목요일, 9월 26, 2019
Medicine, Clinical medicine, Neurotechnology, Neurosurgical procedures, Electrotherapy, Medical devices, Deep brain stimulation, Tourette syndrome, DBS, Policlinico of Milan, Brain stimulation

MILAN, Sept.26, 2019 /PRNewswire/ --Newronika, a spin-off of world-class neurological research centers Policlinico of Milan and University of Milan, has raised an 8.4 million Euros Series-A round.

Key Points: 
  • MILAN, Sept.26, 2019 /PRNewswire/ --Newronika, a spin-off of world-class neurological research centers Policlinico of Milan and University of Milan, has raised an 8.4 million Euros Series-A round.
  • Newronika has developed a closed-loop system for Deep Brain Stimulation (DBS), the first of its kind.
  • The round will allow Newronika to complete its first in man clinical study, get CE-Mark and obtain FDA IDE.
  • "This round puts Newronika straight into the global competition for DBS technology and turns our company into a player to be reckoned with," commented Alain Garcinuo, Newronika's CFO.

Global Deep Brain Stimulation (DBS) Market Outlook 2019-2024 by Stimulation Type, Product, Application, End-user, and Region - ResearchAndMarkets.com

Retrieved on: 
월요일, 8월 26, 2019
Health, General Health, Medicine, Clinical medicine, Branches of biology, Neurotechnology, Electrotherapy, Neurosurgical procedures, Medical devices, Deep brain stimulation, Tourette syndrome, DBS, Brain stimulation, Neuromodulation

The "Deep Brain Stimulation Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Deep Brain Stimulation Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024" report has been added to ResearchAndMarkets.com's offering.
  • The global deep brain stimulation (DBS) market is expected to grow at a CAGR of around 9% during 2019-2024.
  • This latest report provides a deep insight into the global deep brain stimulation (DBS) market covering all its essential aspects.
  • The frequent occurrence of motor & neurological disorders, along with the growing acceptance of minimally invasive (MI) surgeries is the key factor driving the growth of the market.

Metis and Dublin Business School Partner to Deliver the College’s First Internationally Streamed Live Online Course

Retrieved on: 
월요일, 2월 11, 2019
Education, Continuing, Technology, Internet, Professional services, Finance, Training, Other Science, Science, Geography of Europe, Europe, Continents, Dublin Business School, Dublin, DBS, Metis, Republic of Ireland

Dublin Business School (DBS), Ireland's largest independent college, has partnered with leading data science training provider Metis on the college's first internationally delivered live online course, a machine learning module taught live in Dublin by Metis's New York City data science experts.

Key Points: 
  • Dublin Business School (DBS), Ireland's largest independent college, has partnered with leading data science training provider Metis on the college's first internationally delivered live online course, a machine learning module taught live in Dublin by Metis's New York City data science experts.
  • Executive Dean of Dublin Business School, Andrew Conlan-Trant, said, We're really pleased to commence this very exciting collaboration with Metis.
  • Metis accelerates data science learning for individuals, companies, and institutions by providing corporate training and accredited, immersive bootcamps and preparatory courses.
  • Dublin Business School (DBS) is Irelands largest independent higher education and professional training institution.

Boston Scientific Launches Vercise™ Primary Cell And Vercise Gevia™ Deep Brain Stimulation Systems With Directional Leads

Retrieved on: 
목요일, 1월 24, 2019
Medicine, Electromagnetism, Neurotechnology, Electrotherapy, Clinical medicine, Neuroprosthetics, Medical devices, Deep brain stimulation, Tourette syndrome, Electrode, Rechargeable battery, DBS

MARLBOROUGH, Mass., Jan. 24, 2019 /PRNewswire/ --Boston Scientific Corporation (NYSE: BSX) has launched the Vercise Primary Cell (PC) and Vercise Gevia Deep Brain Stimulation (DBS) Systems featuring the Vercise Cartesia Directional Lead.

Key Points: 
  • MARLBOROUGH, Mass., Jan. 24, 2019 /PRNewswire/ --Boston Scientific Corporation (NYSE: BSX) has launched the Vercise Primary Cell (PC) and Vercise Gevia Deep Brain Stimulation (DBS) Systems featuring the Vercise Cartesia Directional Lead.
  • The Vercise Cartesia Directional Lead was the first directional lead introduced to the global market when it launched in Europe in 2015.
  • The new systems featuring the Vercise Cartesia Directional Lead leverage eight individually controlled electrodes on each lead to offer stimulation that can adapt to impedance changes within the brain.
  • "The newly approved Vercise Directional DBS Systems offer smaller devices, are engineered for longer rechargeable battery life and more customizable stimulation compared to other similar systems currently in the market.

Boston Scientific launches GUIDE™ XT System for Visualization of Deep Brain Stimulation in Europe

Retrieved on: 
수요일, 9월 26, 2018
Medicine, Clinical medicine, Neurotechnology, Electrotherapy, Medical devices, Neurosurgical procedures, Deep brain stimulation, Neuroprosthetics, XT, Neurosurgery, DBS, Brain stimulation

EDINBURGH, Scotland, Sept. 26, 2018 /PRNewswire/ --Boston Scientific Corporation (NYSE: BSX) today announced the launch of the GUIDE XT System for visualization of Deep Brain Stimulation (DBS) in Europe.

Key Points: 
  • EDINBURGH, Scotland, Sept. 26, 2018 /PRNewswire/ --Boston Scientific Corporation (NYSE: BSX) today announced the launch of the GUIDE XT System for visualization of Deep Brain Stimulation (DBS) in Europe.
  • The GUIDE XT System is the first DBS visualization system built for directionality that utilizes patient specific anatomy and stimulation field modeling.
  • The GUIDE XT System automatically detects the location of the leads, implanted by a neurosurgeon, in the imaging of the brain.
  • "Unlike visualization systems that use a generic atlas, the GUIDE XT System enables us to visualize the lead placement in the patient's brain.

Abbott Expands its Directional Deep Brain Stimulation Therapy by Offering New MR-Conditional Labeling

Retrieved on: 
목요일, 8월 2, 2018
Medicine, Clinical medicine, Neurotechnology, Electrotherapy, Neurosurgical procedures, Medical devices, Deep brain stimulation, Neuroprosthetics, DBS

Prior to the latest Abbott approval, people new to deep brain stimulation (DBS) therapy or those living with older systems from other manufacturers may have experienced barriers in accessing the most advanced DBS therapy options because of the potential need for an MRI in the future.

Key Points: 
  • Prior to the latest Abbott approval, people new to deep brain stimulation (DBS) therapy or those living with older systems from other manufacturers may have experienced barriers in accessing the most advanced DBS therapy options because of the potential need for an MRI in the future.
  • With its updated labeling, Abbott has addressed this challenge with the Infinity DBS system's improved therapy platform the first and only FDA-approved MR-conditional directional DBS system.
  • Abbott's Infinity DBS system with directional leads is designed to direct stimulation toward targeted areas of the brain to maximize patient outcomes and limit side effects.
  • "The combination of directional lead therapy, MRI capability and simplicity in optimized programming could lead to a new standard of care for DBS therapy."